A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Kivu Bioscience Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Kestrel Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Montefiore Medical Center
National Cancer Institute (NCI)
AbbVie
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
City of Hope Medical Center
Nammi Therapeutics Inc
National Institutes of Health Clinical Center (CC)
Revolution Medicines, Inc.
Seagen Inc.
University of California, San Diego
Pfizer
M.D. Anderson Cancer Center
PanTher Therapeutics
Alterome Therapeutics, Inc.
Arcus Biosciences, Inc.
Amgen
Pheon Therapeutics
NYU Langone Health
Eli Lilly and Company
ImmunityBio, Inc.
M.D. Anderson Cancer Center
Institut Paoli-Calmettes
Arbele Limited
UNC Lineberger Comprehensive Cancer Center
RasCal Therapeutics, Inc.
Continuity Biosciences, LLC
Washington University School of Medicine
Eli Lilly and Company
Tomsk National Research Medical Center of the Russian Academy of Sciences
Institute of Cancer Research, United Kingdom
University of California, Davis
ViroMissile, Inc.
Erasca, Inc.
Changhai Hospital
Washington University School of Medicine
Case Comprehensive Cancer Center
Baylor Research Institute